AG10 for Cardiomyopathy

Phase 2

Waitlist Available

Research Sponsored by Eidos Therapeutics, a BridgeBio company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

Females who are pregnant or breastfeeding. Lactating females must agree to discontinue nursing before the study drug is administered

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 60 months or study completion by recommendation from safety monitoring committee

Awards & highlights

No Placebo-Only Group

Summary

This trial will study the long-term effects of AG10 on people with heart failure.

Who is the study for?

This trial is for patients with cardiomyopathy who have completed a prior AG10 study. Participants must be stable enough to follow the treatment plan and agree to use contraception if necessary. Those at risk of heart transplant, on certain other treatments, or with significant health risks are excluded.

What is being tested?

The study tests the long-term safety and effects of AG10 in individuals with cardiomyopathy while they continue their usual heart failure therapy. It's an open-label trial, meaning both researchers and participants know what treatment is being given.

What are the potential side effects?

While specific side effects aren't listed here, potential risks may include reactions related to heart function or interactions with existing medications. As it's a safety study, monitoring for any adverse effects will be a key part of the trial.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am not pregnant or breastfeeding, or I agree to stop breastfeeding to participate.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 60 months or study completion by recommendation from safety monitoring committee

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 60 months or study completion by recommendation from safety monitoring committee

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 60 months or study completion by recommendation from safety monitoring committee for reporting.